patients with first treated or recurrent metastatic breast cancer, according to RECIST version 1.1 standard, confirmed by CT or MRI, have at least one measurable lesion.
HER2 positive or triple negative patients; (IHC++, fish amplification)
Patients with anti-HER2 treatment as first-line or not, and patients with HER2 positive can be treated with adjuvant therapy containing trastuzumab.
You may not be if
\-
Clareo Health | Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
